Drug Profile
Research programme: megakaryocyte progenitor cell therapeutics - Cellerant Therapeutics
Alternative Names: CLT-009 - Cellerant TherapeuticsLatest Information Update: 28 Oct 2018
Price :
$50
*
At a glance
- Originator Cellerant Therapeutics
- Class Cell therapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Acute radiation syndrome; Thrombocytopenia
Most Recent Events
- 28 Oct 2018 No recent reports of development identified for preclinical development in Acute-radiation-syndrome in USA (Parenteral)
- 16 Jul 2016 No recent reports of development identified for preclinical development in Thrombocytopenia in USA (Parenteral)
- 11 Sep 2014 Preclinical trials in Acute radiation syndrome in USA (Parenteral)